Treatment of Sarcomatous Kidney Cancer That is Metastatic in Adults With Doxorubicin and Ifosfamide. Phase II Study
OBJECTIVES: I. Determine the efficacy in terms of objective response after treatment with
ifosfamide and doxorubicin in patients with metastatic sarcomatoid renal cell cancer. II.
Determine the toxicity of this regimen in these patients. III. Determine the effect of this
regimen on the survival of these patients.
OUTLINE: This is a multicenter study. Patients receive doxorubicin IV on day 1 and
ifosfamide IV over 2 hours on days 1 and 2. Treatment is repeated every 3 weeks for up to 8
courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 3 years.
Primary Purpose: Treatment
Stephane Culine, MD
Centre Val d'Aurelle - Paul Lamarque
United States: Federal Government